var data={"title":"Fluorouracil and salicylic acid (topical) (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluorouracil and salicylic acid (topical) (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/793204?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluorouracil-and-salicylic-acid-topical-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluorouracil and salicylic acid (topical) (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247201\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimetabolite;</li>\n      <li>\n        Antineoplastic Agent, Antimetabolite (Pyrimidine Analog);</li>\n      <li>\n        Keratolytic Agent;</li>\n      <li>\n        Topical Skin Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247248\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkeratotic actinic keratosis: </b>Topical: Apply once daily until lesions have cleared or a maximum duration of 12 weeks. May treat up to 10 lesions at the same time; however, the total treatment area should not exceed 25 cm&sup2;.  Larger areas should be treated at different periods with the most symptomatic area treated first. Less frequent application (3 per week) may be required when used on areas of thin epidermis (eg, around eyes and temples) or if serious adverse reactions occur. Optimal therapeutic response may not be observed for up to 8 weeks after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> In case of a missed dose, do not apply an extra dose, but continue treatment according to the regular schedule.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247249\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247250\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247251\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247287\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, External:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Actikerall: Fluorouracil 0.5% and salicylic acid 10% (25 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247286\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247253\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: For external use only. Not intended for oral, ophthalmic, intranasal, intravaginal, intra-auditory canal, or intra-anal use. Apply solution to the face, forehead, and/or bald scalp with the provided brush applicator connected to the closure cap. To avoid overloading the brush with solution, wipe the brush on the neck of the bottle before application. Allow solution to dry to form a film over the treated area. Do not cover treated area after application. Just prior to each reapplication, remove any remaining film coating by peeling it off; warm water may be used if needed. Avoid contact with healthy skin. Do not apply to bleeding lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247266\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Fluorouracil is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247217\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkeratotic actinic keratosis: </b>Treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) of the face, forehead, and balding scalp in immunocompetent adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132865\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Local: Application site irritation (86%; severe: 21%), local inflammation (73%; severe: 16%), application-site pruritus (45%; severe: 5%), application site pain (25%; severe: 4%), application site erythema (11%; severe: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Crusted skin (3%; scab), desquamation (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Skin erosion (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Application site reaction (including dermatitis, eczema, edema, exfoliation, scar, and ulcer), contact dermatitis, eye pruritus, gastroenteritis, hypersensitivity reaction, increased lacrimation, influenza, papule, pruritus, skin rash, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247227\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluorouracil, capecitabine, salicylic acid or other salicylates, or any component of the formulation; use in eyes or mucous membranes; women who are or may become pregnant; breast-feeding; renal impairment; concomitant use with dihydropyrimidine dehydrogenase (DPD) enzyme inhibitors; patients with known DPD deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247228\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local skin reactions: Localized skin reactions such as erythema, inflammation, irritation (including burning), pain, pruritus, bleeding, and erosion may occur. Reactions are typically mild or moderate but severe reactions have been observed. Increased absorption through skin with a thin epidermis is possible and may lead to an increase in incidence and frequency of adverse reactions. Avoid use on bleeding lesions. Concurrent use with topical products with drying, peeling, desquamating, or abrasive properties may result in cumulative irritant/drying effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Avoid prolonged exposure to sunlight or UV irradiation during treatment; reaction intensity may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dihydropyrimidine dehydrogenase enzyme deficiency: Individuals lacking dihydropyrimidine dehydrogenase (DPD) enzyme activity may exhibit severe toxicity with topical fluorouracil; signs/symptoms of toxicity may include nausea, vomiting, diarrhea, stomatitis, esophagopharyngitis, GI ulceration and bleeding, hemorrhage (from any site), thrombocytopenia, and agranulocytosis. Discontinue use immediately if toxicity is observed or suspected and wash treated area with warm water; patient should seek prompt medical attention. Use is contraindicated in patients with known DPD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dimethylsulfoxide: Product may contain dimethylsulfoxide, which can cause skin irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Safety and efficacy has not been evaluated in the treatment of recurring lesions or on body parts other than the face, forehead, and bald scalp; has not been evaluated for treatment in basal cell carcinoma or in Bowen disease. Avoid topical application to mucous membranes due to potential for local inflammation and ulceration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132779\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132776\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=111317&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Fluorouracil (Topical) may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemcitabine: May increase the serum concentration of Fluorouracil (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Fluorouracil (Topical) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May decrease the serum concentration of Fluorouracil (Topical). SORAfenib may increase the serum concentration of Fluorouracil (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fluorouracil (Topical) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247218\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are or may become pregnant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247302\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are breast-feeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247307\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49247242\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Response may be observed as early as 6 weeks; complete healing may not be evident for up to 8 weeks after treatment cessation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Fluorouracil: Minimal percutaneous absorption (0.035%) through intact skin; also see individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49228430\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actikerall (AT, CH, CZ, DE, DK, EE, ES, GB, LT, MX, NO, PL, PT, SE, SK);</li>\n      <li>Verrucare (PT);</li>\n      <li>Verrufilm (LB);</li>\n      <li>Verruma Hermal (GR);</li>\n      <li>Verrumal (AE, CH, CZ, HU, IL, JO, KR, PT, QA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actikerall (fluorouracil and salicylic acid) [product monograph]. Mississauga, ON, Canada: Cipher Pharmaceuticals Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed December 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 111317 Version 4.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F49247201\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F49247248\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F49247249\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F49247250\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F49247251\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49247287\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49247286\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49247253\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49247266\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49247217\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46132865\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49247227\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F49247228\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46132779\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46132776\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F49247218\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F49247302\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F49247307\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F49247242\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49228430\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/111317|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluorouracil-and-salicylic-acid-topical-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Fluorouracil and salicylic acid (topical) (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}